To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.
[Cell Chemical Biology]
7992332
{7992332:EEEEEEEE}
apa
50
1
168889
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/